Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability...
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints )
Also on site :
- Adorable Elephant Breaks Free From National Park and Heads Right to the Snack Aisle at the Grocery Store
- Chicago Forecast: Pleasant temperatures, mostly cloudy skies ahead of possible evening rain
- Yemen’s al-Qaida branch leader threatens Trump, Musk and others